It will also be critical to determine if LSD1-CoREST2-STAT3 plays a role in cell plasticity in other subtypes of CRC or if it is restricted to BRAF mutant CRC treated with BRAFi + EGFRi as these findings will inform the group of CRC patients that have the potential to benefit from LSD1 inhibitor therapy. This evidence concerns the gene STAT3 and colorectal carcinoma.